METHOD AND SYSTEM FOR REDUCING THE LIKELIHOOD OF DEVELOPING LIVER CANCER IN AN INDIVIDUAL DIAGNOSED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

• US 20190117709A1
• Filed: 12/21/2018
• Published: 04/25/2019
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik
• Inventors: Kovarik, Joseph E.
• Granted Patent: US 10,512,661 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual'"'"'s gut microbiome are reduced.

Claims

1. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:

providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;

administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.

2. The method as set forth in claim 5, wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.

3. The method as set forth in claim 1, wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.

4. The method as set forth in claim 1, further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

5. The method as set forth in claim 1, further comprising increasing the levels of Roseburia, while reducing the levels of Akkermansia spp. in the individual'"'"'s gut microbiome.

6. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:

providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;

administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

7. The method as set forth in claim 6, further comprising increasing the levels of Roseburia, while reducing the levels of Akkermansia spp. in the individual'"'"'s gut microbiome.

8. The method as set forth in claim 6, wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.

9. The method as set forth in claim 6, wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.

10. A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease, comprising:

providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;

administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

increasing the levels of Roseburia, while reducing the levels of Akkermansia spp. in the individual'"'"'s gut microbiome.

11. The method as set forth in claim 10, further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

12. The method as set forth in claim 10, wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.

13. The method as set forth in claim 10, wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.